April 25, 2025
After volatility surges, expect a sooner-or-later purge!
I might be early, fortify the portfolio as earnings are a’comin’
News: Caribou Biosciences (CRBU) announced reducing its workforce by 32% and cost reductions estimated to be $2.5 to $3.5 M to focus resources on its lead oncology clinical programs CB-010 and CB-011, with clinical data disclosures now planned for H2/25.
Pre-open Indications: 1 Sell into Strength and 4 Negative
No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief
Never leave an investor uninformed!
April 25, 2025
Newer: Banging the drum for a Ponzi scheme designation (not the first time, maybe the 25th) as share pricing jumps +$0.03 with 3,273 shares traded on 4/25/25 ...
New: On April 11, 2025, Marcum LLP (their accountants) informed Harvard Apparatus Regenerative Technology (OTCQB: HRGN) that Marcum resigned as the Registrant’s independent registered public accounting firm. Also on April 11, 2025, the Registrant, with the approval of the Audit Committee of the Registrant’s Board of Directors, engaged CBIZ CPAs P.C. as the Registrant’s independent registered public accounting firm.
Following a MAJOR question, "WHAT happens to OTCQB: HRGN if the White House and the new head of the SEC starts to "DELIST" Chinese companies???
Under the Holding Foreign Companies Accountable Act, the SEC can ban foreign companies from trading ..."
Wall Street Journal, 4/21/25 ... "Many investors would opt to SELL their stakes in Chinese firms if they are delisted"
April 25, 2025
Q1/25 earnings are a’comin’ as LPS (loss-per-share) expectations and estimates re-surface
While many cell and gene therapy companies initiate operational and capital spending reductions
Q1/25 earnings beginning to be posted: MDXG 4/30, ALNY 5/1, AXGN 5/8 and VCEL 5/18
Never leave an investor uninformed!
The week in review
April 25, 2025
Newer: Banging the drum for a Ponzi scheme designation (not the first time, maybe the 25th) as share pricing jumps +$0.03 with 3,273 shares traded on 4/25/25 ... Who's buying a falling knife ... fork and spoon after barely if any trading volume for months -- DST Capital? New: On April 11, 2025, Marcum LLP (their accountants) informed Harvard Apparatus Regenerative Technology (OTCQB: HRGN) that Marcum resigned as the Registrant’s independent registered public accounting firm. Also on April 11, 2025, the Registrant, with the approval of the Audit Committee of the Registrant’s Board of Directors, engaged CBIZ CPAs P.C. as the Registrant’s independent registered public accounting firm. Marcum’s LLP had reported the addition of a paragraph expressing substantial doubt about the Company’s ability to continue as a going concern. Following a MAJOR question, "WHAT happens to OTCQB: HRGN if the White House and the new head of the SEC starts to "DELIST" Chinese companies??? Under the Holding Foreign Companies Accountable Act, the SEC can ban foreign companies from trading ..." Wall Street Journal, 4/21/25 ... "Many investors would opt to SELL their stakes in Chinese firms if they are delisted"
March 10, 2025
including pre-funded warrants to purchase 1,404,988 shares of common stock at an offering price of $28.47 per pre-funded warrant with an exercise price of $0.01 per share. BEAM closed Friday at $1.23 to $28.48 with a pre-open indication of $2.57 or +0.02% to $31.05 Gross proceeds from the offering are expected to be approximately $500.0 million expected to close on or about 3/11/2525
February 18, 2025
35.739 M shares were priced at $4.30 with 13.88 M warrants priced at $4.029 Tuesday SLDB jumped +$1.27 to $5.30 The financing includes new and existing investors, including Adage Capital Partners LP, Bain Capital Life Sciences, Invus, Perceptive Advisors, RA Capital Management, TCGX, Venrock Healthcare Capital Partners, Vestal Point Capital, a U.S.-based life-sciences focused institutional investor, a major mutual fund and a large investment management firm.
April 25, 2025
RegMed Investors (RMi) Closing Bell: sector pricing deteriorated with profit-taking
April 25, 2025
RegMed Investors’ (RMi) pre-open: Make a buck Friday
April 24, 2025
RegMed Investors (RMi) Closing Bell: watch, wait and appreciate as sector stays stabilized
April 24, 2025
RegMed Investors’ (RMi) pre-open: after back-to-back-to-back gains, pain usually ensues
April 23, 2025
RegMed Investors (RMi) Closing Bell: Bada bing
April 23, 2025
RegMed Investors’ (RMi) pre-open: the tweets and tariff spins escalate optionality of markets and sector
April 22, 2025
RegMed Investors (RMi) Closing Bell: uncle algo and his electronic trading dwarfs are friends with benefits today
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
